Piper Sandler Maintains Overweight on Tenax Therapeutics, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 78.4%

Neg 0% Neu 0% Pos 78.4%

Piper Sandler analyst Yasmeen Rahimi maintains Tenax Therapeutics (NASDAQ:TENX) with a Overweight and raises the price target from $20 to $50.